Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Mitochondrial dysfunction and risk of cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Impaired lipolysis in propionic acidemia: A new metabolic myopathy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increased risk of sudden death in untreated Primary Carnitine Deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Absence of p.R50X Pygm read-through in McArdle disease cellular models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Mitochondrial mutations are commonly reported in tumours, but it is unclear whether impaired mitochondrial function per se is a cause or consequence of cancer. To elucidate this, we examined the risk of cancer in a nationwide cohort of patients with mitochondrial dysfunction.

METHODS: We used nationwide results on genetic testing for mitochondrial disease and the Danish Civil Registration System, to construct a cohort of 311 patients with mitochondrial dysfunction. A total of 177 cohort members were identified from genetic testing and 134 genetically untested cohort members were matrilineal relatives to a cohort member with a genetically confirmed maternally inherited mDNA mutation. Information on cancer was obtained by linkage to the Danish Cancer Register. Standardised incidence ratios (SIRs) were used to assess the relative risk of cancer.

RESULTS: During 7334 person-years of follow-up, 19 subjects developed a primary cancer. The corresponding SIR for any primary cancer was 1.06 (95% confidence interval 0.68-1.63). Subgroup analyses according to mutational subtype yielded similar results, for example, a SIR of 0.94 (95% CI 0.53 to 1.67) for the m.3243A>G maternally inherited mDNA mutation, cases=13.

CONCLUSIONS: Patients with mitochondrial dysfunction do not appear to be at increased risk of cancer compared with the general population.

OriginalsprogEngelsk
TidsskriftB J C
Vol/bind112
Udgave nummer6
Sider (fra-til)1134-40
Antal sider7
ISSN0007-0920
DOI
StatusUdgivet - 17 mar. 2015

ID: 45806953